Tags

Type your tag names separated by a space and hit enter

Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
Expert Rev Anti Infect Ther. 2012 Oct; 10(10):1087-103.ER

Abstract

The growing prevalence of resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus continues to pose a dilemma to clinicians. With strains developing reduced susceptibility to vancomycin, effective and well-tolerated antibiotics to combat these resistant pathogens are needed. Ceftaroline is a new parenteral cephalosporin that has been available in the USA for almost 2 years. Similar to other cephalosporins, it is well tolerated with mostly mild adverse events; however, compared with existing parenteral cephalosporins, ceftaroline has the unique attribute of being bactericidal against resistant Gram-positive aerobes including both hospital- and community-acquired methicillin-resistant S. aureus, S. aureus strains with reduced susceptibility or complete resistance to vancomycin, and resistant Streptococcus pneumoniae including multidrug-resistant strains. Current indications in the USA and Europe include treatment of adults with complicated skin, skin-structure infections and community-acquired pneumonia. This paper will review the properties of ceftaroline, its spectrum of activity, clinical use, safety profile and future role.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Garrison MW
Washington State University College of Pharmacy, Spokane, WA 99210-1495, USA. garrism@wsu.edu
Kawamura NM
No affiliation info available
Wen MM
No affiliation info available

MeSH

AnimalsAnti-Bacterial AgentsCephalosporinsClinical Trials as TopicCommunity-Acquired InfectionsGram-Positive BacteriaHumansMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsPneumonia, BacterialRabbitsStaphylococcal Infections

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23167512

Citation

Garrison, Mark W., et al. "Ceftaroline Fosamil: a New Cephalosporin Active Against Resistant Gram-positive Organisms Including MRSA." Expert Review of Anti-infective Therapy, vol. 10, no. 10, 2012, pp. 1087-103.
Garrison MW, Kawamura NM, Wen MM. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Rev Anti Infect Ther. 2012;10(10):1087-103.
Garrison, M. W., Kawamura, N. M., & Wen, M. M. (2012). Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Review of Anti-infective Therapy, 10(10), 1087-103. https://doi.org/10.1586/eri.12.112
Garrison MW, Kawamura NM, Wen MM. Ceftaroline Fosamil: a New Cephalosporin Active Against Resistant Gram-positive Organisms Including MRSA. Expert Rev Anti Infect Ther. 2012;10(10):1087-103. PubMed PMID: 23167512.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. AU - Garrison,Mark W, AU - Kawamura,Nathan M, AU - Wen,Mary M, Y1 - 2012/11/21/ PY - 2012/11/22/entrez PY - 2012/11/22/pubmed PY - 2013/5/22/medline SP - 1087 EP - 103 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 10 IS - 10 N2 - The growing prevalence of resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus continues to pose a dilemma to clinicians. With strains developing reduced susceptibility to vancomycin, effective and well-tolerated antibiotics to combat these resistant pathogens are needed. Ceftaroline is a new parenteral cephalosporin that has been available in the USA for almost 2 years. Similar to other cephalosporins, it is well tolerated with mostly mild adverse events; however, compared with existing parenteral cephalosporins, ceftaroline has the unique attribute of being bactericidal against resistant Gram-positive aerobes including both hospital- and community-acquired methicillin-resistant S. aureus, S. aureus strains with reduced susceptibility or complete resistance to vancomycin, and resistant Streptococcus pneumoniae including multidrug-resistant strains. Current indications in the USA and Europe include treatment of adults with complicated skin, skin-structure infections and community-acquired pneumonia. This paper will review the properties of ceftaroline, its spectrum of activity, clinical use, safety profile and future role. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/23167512/Ceftaroline_fosamil:_a_new_cephalosporin_active_against_resistant_Gram_positive_organisms_including_MRSA_ L2 - https://www.tandfonline.com/doi/full/10.1586/eri.12.112 DB - PRIME DP - Unbound Medicine ER -